Hematological malignancies, such as leukemia, lymphoma, and myeloma, are cancers originating in the bone marrow and lymphatic system, marked by the uncontrolled growth of blood cells. Gene therapy offers a revolutionary treatment approach by directly targeting genetic mutations and boosting the body’s anti-tumor immune responses. This study aims to provide a comprehensive overview of hematological cancers and explores the current and emerging gene therapy strategies that are being investigated for their treatment. It also provides a detailed overview of gene delivery systems, their principles, types, and recent advancements in gene therapy as a potential treatment strategy. It provides a detailed analysis of gene delivery systems, therapeutic modalities, and clinical applications, with a focus on CAR-T, CRISPR-Cas9, and RNA interference (RNAi) technologies. It highlights recent advances in gene delivery, including viral and non-viral vector systems, along with advanced techniques like gene editing and gene silencing. Special attention is given to cutting-edge techniques such as CRISPR-Cas9, CAR-T therapies, and RNA interference. The article concludes by discussing current hurdles and prospects of gene therapy, emphasizing its immense potential to transform the treatment for hematological cancer.

The fast-growing field of nanotheranostics is revolutionizing cancer treatment by allowing for precise diagnosis and targeted therapy at the cellular and molecular levels. These nanoscale platforms provide considerable benefits in oncology, including improved disease and therapy specificity, lower systemic toxicity, and real-time monitoring of therapeutic outcomes. However, nanoparticles' complicated interactions with biological systems, notably the immune system, present significant obstacles for clinical translation. While certain nanoparticles can elicit favorable anti-tumor immune responses, others cause immunotoxicity, including complement activation-related pseudoallergy (CARPA), cytokine storms, chronic inflammation, and organ damage. Traditional toxicity evaluation approaches are frequently time-consuming, expensive, and insufficient to capture these intricate nanoparticle-biological interactions. Artificial intelligence (AI) and machine learning (ML) have emerged as transformational solutions to these problems. This paper summarizes current achievements in nanotheranostics for cancer, delves into the causes of nanoparticle-induced immunotoxicity, and demonstrates how AI/ML may help anticipate and create safer nanoparticles. Integrating AI/ML with modern computational approaches allows for the detection of potentially dangerous nanoparticle qualities, guides the optimization of physicochemical features, and speeds up the development of immune-compatible nanotheranostics suited to individual patients. The combination of nanotechnology with AI/ML has the potential to completely realize the therapeutic promise of nanotheranostics while assuring patient safety in the age of precision medicine.

Over 90% of cancer-related mortality worldwide is due to metastatic disease since the dynamic tumor microenvironment poses huge challenges in preventing the spread of metastatic cancer. Introducing the advent of advance biomaterials and their swift evolution, this review highlights the great potential of innovative biomaterials to proficiently tackle the metastatic tumor environment. Focusing on four distinct categories of biomaterials systems, action mechanism of biomaterials utilized in anti-tumor therapy is explained in detail: 1. Nanoplatforms sensitive to biochemical cues including pH, redox, and enzymes are known as stimuli-responsive nanoplatforms that react according their environment, 2. Smart nanoplatforms changing their morphology to penetrate impermeable physical barriers at tumor site, 3. Ingenious biomaterial participating in tumor normalization, and 4. Nanoplatforms with real-time theranostic capabilities due to innate feedback-loop mechanism. Ingeniously structured biomaterials with extensive evidence in preclinical efficacy encourage their inclusion in metastatic tumor therapy however, their utilization in medical settings is prevented due to various challenges; impractical manufacturing cost, regulatory and safety issues as well as large-scale production are major challenges restraining their widespread use. A concrete framework is proposed in this review to accelerate the biomaterial structure standardization process, following the GMP and other regulatory guidelines with the aim of implementing biomaterial-based tumor diagnostics and therapies. Since incorporating advancing technologies in tumor therapy such AI-driven, autonomous biomaterial structure or patient-specific tumor models would enable confront the proliferating metastatic tumor cases.